Radiopharm Theranostics is an Australian clinical-stage biopharmaceutical company that develops radiopharmaceuticals for cancer imaging and therapy. The company focuses on theranostics, a modality that attaches radioactive isotopes to targeting molecules—such as antibodies, nanobodies, and peptides—to selectively bind to cancer cells for diagnostic imaging or targeted radiation delivery. Radiopharm is pre-revenue with no approved products; its operations consist entirely of clinical trials and research and development. Its pipeline targets solid tumors, including brain metastases, breast cancer, non-small cell lung cancer, pancreatic cancer, and prostate cancer, across five licensed platforms and a joint venture with MD Anderson Cancer Center. Radiopharm's business model centers on in-licensing technologies from academic and research institutions, managing clinical development, and preparing assets for commercialization either directly or through strategic partners. The company conducts early-stage trials in Australia before advancing later-stage trials in the United States. Radiopharm funds its pipeline through equity offerings and co-development and licensing collaborations with partners such as Lantheus.